{"analyses":[{"ciLowerLimit":"10.92","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"29.08","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0002","paramType":"Common Risk Difference on Response Rate","paramValue":"20.00","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"2.002","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"12.844","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0002","paramType":"Odds Ratio (OR)","paramValue":"5.071","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"21.14","upperLimit":"35.93","value":"28.10"},{"groupId":"OG001","lowerLimit":"2.95","upperLimit":"16.40","value":"7.89"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"76"}],"units":"Participants"}],"description":"RBC-TI Response was defined as the absence of any Red Blood Cells (RBC) transfusion during any consecutive 84-day (12-week) period (ie, Days 1 to 84, Days 2 to 85, Days 3 to 86, etc.) during the first 24 weeks of treatment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Luspatercept 1.0 mg/Kg SC on Day 1 of each 21-day treatment cycle","id":"OG000","title":"Luspatercept"},{"description":"Placebo (Volume equivalent to experimental arm) SC on Day 1 of each 21-day treatment cycle","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"All treated participants","reportingStatus":"POSTED","timeFrame":"From Week 1 through Week 24 of study treatment","title":"Percentage of Participants Who Achieved Red Blood Cell Transfusion Independence (RBC-TI) ≥ 12 Weeks From Week 1 to Week 24","type":"SECONDARY","unitOfMeasure":"Percent of Participants"}